RBI Call/Frequentis 23-25/ AT0000A375W2 /
14/05/2024 09:15:01 | Chg.-0.006 | Bid13:30:52 | Demandez à13:30:52 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
0.138EUR | -4.17% | 0.122 Bid taille: 10,000 |
0.142 Ask la taille: 10,000 |
FREQUENTIS AG | 31.00 EUR | 21/03/2025 | Call |
GlobeNewswire
13:45
Global Technologies, Ltd. Announces Its Financial Results for the Quarter Ended March 31, 2024 and t...
Newsfile Corp
13:44
Appia Announces Encouraging Initial Results from the Newly Identified Taygeta and Merope Exploration...
GlobeNewswire
13:30
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire
13:30
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enable...
GlobeNewswire
13:30
ETFS Capital Calls on WisdomTree to Stop Fighting Stockholders and Run a Strategic Process
GlobeNewswire
13:30
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Tr...
GlobeNewswire
13:30
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
GlobeNewswire
13:30
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
GlobeNewswire
13:30
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
13:30
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 20...
GlobeNewswire
13:30
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
GlobeNewswire
13:30
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
13:30
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page